Multiple sclerosis in 2020: un bon cru.

Maillart, Elisabeth; Lubetzki, Catherine

Maillart, Elisabeth; Lubetzki, Catherine.

Maillart E; Assistance Publique des Hôpitaux de Paris, Sorbonne University, Paris Brain Institute, Groupe Hospitalier Pitié-Salpêtrière, Paris 75013, France.
Lubetzki C; Assistance Publique des Hôpitaux de Paris, Sorbonne University, Paris Brain Institute, Groupe Hospitalier Pitié-Salpêtrière, Paris 75013, France. Electronic address: catherine.lubetzki@aphp.fr.

Lancet Neurol ; 20(1): 12-13, 2021 01.

Article in English | MEDLINE | ID: covidwho-1023778

Subject(s)

Multiple Sclerosis/diagnostic imaging; Multiple Sclerosis/therapy; Neuroprotective Agents/pharmacology; Animals; COVID-19/epidemiology; Clinical Trials as Topic; Humans; Multiple Sclerosis/drug therapy; Multiple Sclerosis/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neuroprotective Agents / Multiple Sclerosis Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Animals / Humans Language: English Journal: Lancet Neurol Journal subject: Neurology Year: 2021 Document Type: Article Affiliation country: S1474-4422(20)30441-5

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google